[go: up one dir, main page]

ES2115626T3 - Anticuerpo monoclonal humano especifico al antigeno de superficie de la membrana de las celulas cancerosas. - Google Patents

Anticuerpo monoclonal humano especifico al antigeno de superficie de la membrana de las celulas cancerosas.

Info

Publication number
ES2115626T3
ES2115626T3 ES92110841T ES92110841T ES2115626T3 ES 2115626 T3 ES2115626 T3 ES 2115626T3 ES 92110841 T ES92110841 T ES 92110841T ES 92110841 T ES92110841 T ES 92110841T ES 2115626 T3 ES2115626 T3 ES 2115626T3
Authority
ES
Spain
Prior art keywords
monoclonal antibody
cell membrane
cancer cell
human monoclonal
surface antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92110841T
Other languages
English (en)
Inventor
Saiko Hosokawa
Toshiaki Tagawa
Yoko Hirakawa
Norihiko Ito
Kazuhiro Nagaike
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Chemical Corp
Original Assignee
Mitsubishi Chemical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mitsubishi Chemical Corp filed Critical Mitsubishi Chemical Corp
Application granted granted Critical
Publication of ES2115626T3 publication Critical patent/ES2115626T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/812—Liposome comprising an antibody, antibody fragment, antigen, or other specific or nonspecific immunoeffector
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/863—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving IgM
    • Y10S530/864—Monoclonal
    • Y10S530/865—Human
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/867—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody produced via recombinant dna technology

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biochemistry (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

SE PRESENTA UN ANTICUERPO MONOCLONAL HUMANO QUE SE UNE A UN ANTIGENO SUPERFICIAL DE UNA MEMBRANA DE UNA CELULA CANCERIGENA, UN DNA AISLADO QUE CODIFICA EL ANTICUERPO, Y UN HIBRIDOMA QUE PRODUCE EL ANTICUERPO. TAMBIEN SE PRESENTA UNA FORMULACION ANTICACERIGENA QUE COMPRENDE EL ANTICUERPO MONOCLONAL UNIDO A LA SUPERFICIE DE UN LIPOSOMA QUE ENCIERRA UN AGENTE O TOXINA ANTICANCERIGENA.
ES92110841T 1991-06-28 1992-06-26 Anticuerpo monoclonal humano especifico al antigeno de superficie de la membrana de las celulas cancerosas. Expired - Lifetime ES2115626T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP15885991 1991-06-28
JP15886191 1991-06-28
JP15886091 1991-06-28

Publications (1)

Publication Number Publication Date
ES2115626T3 true ES2115626T3 (es) 1998-07-01

Family

ID=27321422

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92110841T Expired - Lifetime ES2115626T3 (es) 1991-06-28 1992-06-26 Anticuerpo monoclonal humano especifico al antigeno de superficie de la membrana de las celulas cancerosas.

Country Status (5)

Country Link
US (5) US5767246A (es)
EP (1) EP0520499B1 (es)
CA (1) CA2072249C (es)
DE (1) DE69224496T2 (es)
ES (1) ES2115626T3 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2192426A1 (es) * 2000-05-11 2003-10-01 Univ Vigo Anticuerpo monoclonal humano sm50/20 que reconoce leucocitos humanos, y su uso en terapia.
WO2007034022A1 (es) * 2005-09-19 2007-03-29 Daniel Serrano Gil Una composicion para ser administrada a un mamifero o a un ser humano

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane
EP0652775B1 (en) * 1992-07-27 2000-04-19 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Targeting of liposomes to the blood-brain barrier
JP3351476B2 (ja) * 1993-01-22 2002-11-25 三菱化学株式会社 リン脂質誘導体及びそれを含有するリポソーム
FR2706486B1 (fr) * 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
US6825320B1 (en) 1995-03-29 2004-11-30 Millenium Pharmaceuticals, Inc. FOHY03 polypeptides
US6794185B1 (en) 1995-03-29 2004-09-21 Millennium Pharmaceuticals, Inc. fohy030 nucleic acid molecules
US5633161A (en) * 1995-03-29 1997-05-27 Millennium Pharmaceuticals, Inc. Murine gene fomy030 coding for tumor progression inhibitor
US6251597B1 (en) 1996-03-29 2001-06-26 Millennium Pharmaceuticals, Inc. Methods for detecting fohy030
US6312909B1 (en) * 1996-03-29 2001-11-06 Millennium Pharmaceuticals, Inc. Compositions and methods for the diagnosis prevention and treatment of tumor progression
KR19990029749A (ko) * 1997-09-17 1999-04-26 미우라 아끼라 2가 반응성 수용성 고분자 유도체 및 이들을 함유하는 복합체
GB9814383D0 (en) * 1998-07-02 1998-09-02 Cambridge Antibody Tech Improvements relating to antibodies
CN101088561A (zh) * 1998-07-21 2007-12-19 展马博联合股份有限公司 抗丙型肝炎病毒抗体及其用途
AU3191100A (en) * 1999-03-17 2000-10-04 Mitsubishi Chemical Corporation Ligand-bonded complex
AU3673500A (en) * 1999-04-08 2000-11-14 Mitsubishi Chemical Corporation Fine particles targeting cells and process for producing the same
JP4111368B2 (ja) * 1999-04-23 2008-07-02 三菱化学株式会社 抗体およびポリアルキレングリコール結合リポソーム
JP2004506604A (ja) * 2000-03-17 2004-03-04 ザ・ユニバーシティ・オブ・テネシー・リサーチ・コーポレイション Ｌｐａ受容体作用薬および拮抗薬ならびにこれらの使用法
ATE322501T1 (de) * 2000-11-27 2006-04-15 Rmf Dictagene Sa Verfahren zur rückfaltung von chemisch hergestellten polypeptiden
JP4171816B2 (ja) 2001-01-26 2008-10-29 インヒビテックス インコーポレーテッド Ｃｌｆａタンパク質に対するモノクローナル抗体および感染症を処置または予防することにおける使用の方法
JPWO2003010542A1 (ja) * 2001-07-25 2004-11-18 三菱ウェルファーマ株式会社 癌診断薬
US20050037061A1 (en) * 2001-07-25 2005-02-17 Saiko Hosokawa Remedies for mammary cancer
WO2003040341A2 (en) * 2001-11-07 2003-05-15 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Anti-hepatitis a virus antibodies
CA2468971A1 (en) * 2001-12-04 2003-06-12 Mitsubishi Pharma Corporation Method of activating protein
AU2003271093A1 (en) 2002-10-04 2004-11-01 Mitsubishi Pharma Corporation Antigen recognizing antibody
CA2511228A1 (en) * 2002-12-20 2004-07-08 Mitsubishi Pharma Corporation Method of protecting thiol group of protein
AU2003288675B2 (en) * 2002-12-23 2010-07-22 Medimmune Limited Antibodies against PD-1 and uses therefor
CA2514125A1 (en) 2003-01-24 2004-08-12 Elan Pharmaceuticals, Inc. Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents
EP1718310A4 (en) 2004-02-06 2009-05-06 Elan Pharm Inc METHODS AND COMPOSITIONS FOR TREATING TUMORS AND METASTATIC DISEASE
WO2006030602A1 (ja) * 2004-09-16 2006-03-23 Mitsubishi Pharma Corporation 卵巣癌の診断および／または治療薬
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
GB0607798D0 (en) * 2006-04-20 2006-05-31 Alligator Bioscience Ab Novel polypeptides and use thereof
EP2952522B1 (en) 2007-01-31 2019-10-30 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
ES2610531T3 (es) 2007-03-28 2017-04-28 President And Fellows Of Harvard College Polipéptidos cosidos
CA2700808C (en) 2007-09-27 2017-11-14 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20110070298A1 (en) 2008-06-05 2011-03-24 Immunovaccine Technologies Inc. Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance
GB0905790D0 (en) 2009-04-03 2009-05-20 Alligator Bioscience Ab Novel polypeptides and use thereof
US9724337B2 (en) * 2009-04-21 2017-08-08 University Of Kentucky Research Foundation AG-205 for the treatment of breast cancer
AU2010298338A1 (en) 2009-09-22 2012-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2889295A1 (en) 2010-08-12 2015-07-01 New York University Oligooxopiperazines and methods of making and using them
RU2582678C2 (ru) 2010-08-13 2016-04-27 Эйлерон Терапьютикс, Инк. Пептидомиметические макроциклы
SE535296C2 (sv) 2010-09-08 2012-06-19 Anara Ab Mognad av mag-tarmkanalen
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
CN103998058B (zh) 2011-10-06 2021-11-05 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
US8987414B2 (en) 2012-02-15 2015-03-24 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
MX362492B (es) 2012-02-15 2019-01-21 Aileron Therapeutics Inc Macrociclos peptidomiméticos.
CN104334541A (zh) 2012-02-16 2015-02-04 纽约大学 使用低聚氧代哌嗪非肽螺旋模拟物对低氧诱导基因表达的控制
AU2013337388B2 (en) 2012-11-01 2018-08-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
GB201219678D0 (en) 2012-11-01 2012-12-12 Benf Ab Ketone body inhibitors and uses thereof
WO2015123654A1 (en) 2014-02-17 2015-08-20 The Cleveland Clinic Foundation Amine passivated nanoparticles for cancer treatment and imaging
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
KR20170129879A (ko) 2015-03-20 2017-11-27 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP2018528217A (ja) 2015-09-10 2018-09-27 エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Ｍｃｌ−１のモジュレーターとしてのペプチド模倣大環状分子
US11273151B2 (en) 2015-11-04 2022-03-15 Icahn School Of Medicine At Mount Sinai Methods of treating tumors and cancer, and identifying candidate subjects for such treatment
EP3448881B1 (en) 2016-04-26 2023-06-07 Icahn School of Medicine at Mount Sinai Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4761377A (en) * 1984-10-15 1988-08-02 The Regents Of The University Of California Human-human hybrid cell lines that produce antibodies against antigenic determinants on cancer cells
EP0218158A3 (en) * 1985-09-30 1988-12-07 Asahi Kasei Kogyo Kabushiki Kaisha Human monoclonal antibody, B-cell line for producing this antibody and method for preparing this B-cell line and antibody.
EP0232871A3 (en) * 1986-02-07 1989-03-15 Yoshitomi Pharmaceutical Industries, Ltd. Human monoclonal antibody, hybridoma producing the same and its use
JPH0798000B2 (ja) * 1987-05-23 1995-10-25 萩原 義秀 ガン関連抗原特異的ヒト免疫グロブリン
US5145773A (en) * 1989-05-25 1992-09-08 Sloan-Kettering Institute For Cancer Research Method to detect sensitivity to alpha-interferon therapy
CA2069439A1 (en) * 1989-12-15 1991-06-16 Susumu Iwasa Monoclonal antibodies, their production and use
IL97776A (en) * 1990-04-19 2000-10-31 Res Dev Foundation Composition comprising a conjugate of a ZME antibody and a biological response modifier
US5419904A (en) * 1990-11-05 1995-05-30 The Regents Of The University Of California Human B-lymphoblastoid cell line secreting anti-ganglioside antibody
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
CA2072249C (en) * 1991-06-28 2003-06-17 Saiko Hosokawa Human monoclonal antibody specifically binding to surface antigen of cancer cell membrane

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2192426A1 (es) * 2000-05-11 2003-10-01 Univ Vigo Anticuerpo monoclonal humano sm50/20 que reconoce leucocitos humanos, y su uso en terapia.
WO2007034022A1 (es) * 2005-09-19 2007-03-29 Daniel Serrano Gil Una composicion para ser administrada a un mamifero o a un ser humano
ES2272178A1 (es) * 2005-09-19 2007-04-16 Daniel Serrano Gil Una composicion para ser administrada a un mamifero o a un ser humano.
EA016023B1 (ru) * 2005-09-19 2012-01-30 Даниэль Серрано Хил Композиция липосом для введения млекопитающему, в том числе человеку

Also Published As

Publication number Publication date
US6139869A (en) 2000-10-31
CA2072249A1 (en) 1992-12-29
DE69224496D1 (de) 1998-04-02
US5990297A (en) 1999-11-23
US5767246A (en) 1998-06-16
US5990287A (en) 1999-11-23
US5837845A (en) 1998-11-17
EP0520499A1 (en) 1992-12-30
CA2072249C (en) 2003-06-17
EP0520499B1 (en) 1998-02-25
DE69224496T2 (de) 1998-07-09

Similar Documents

Publication Publication Date Title
ES2115626T3 (es) Anticuerpo monoclonal humano especifico al antigeno de superficie de la membrana de las celulas cancerosas.
AR007249A1 (es) Preparacion concentrada de anticuerpos
BR9607171A (pt) Anticorpos monoclonais anti-cd6 e usos dos mesmos
DK0554356T3 (da) Monoklonalt antistof
BR9609072A (pt) Fatores de ativação macrófagos derivados de proteìna ligada a vitamina d clonada
ES2124250T3 (es) Anticuerpo especifico para un antigeno tumoral.
DK0552296T3 (da) Monoklonale antistoffer fra mus
ES2079818T3 (es) Composicion cosmetica en forma de un gel solido.
ES2177509T3 (es) Empleo de anticuerpos para la vacunacion contra el cancer.
DE69938725D1 (de) Monoklonale antikörper gegen das protein g3bp und deren verwendungen
ES2046173T3 (es) Lineas celulares de hibridoma y sus anticuerpos monoclonales con respecto al factor estimulador de colonias de granulocitos pluripotentes humanos.
DE69841331D1 (de) Humanisierte monoklonale antikörper die schützen gegen shigatoxininduzierte krankheiten
IT1264965B1 (it) Uso di alfa 1-bloccanti nel trattamento della eiaculazione precoce
ES2042461T1 (es) Producto y procedimiento para el te\ido oxidativo del cabello.
IL109026A0 (en) Chlamyda vaccine
DE3587714D1 (de) Menschliches alpha 2-Plasmin spezifischer monoklonaler Antikörper.
FI944563A0 (fi) Mikro-organismeja, valmistusmenetelmä ja käyttö
FI934963A0 (fi) CTAA 81AV78, antigen som igenkaenns av monoklonal 87AV78-humanantikropp
EP0836480A4 (en) COMPOSITIONS THAT PROVIDE ADP-RIBOSYL TRANSFERASE ACTIVITY AND METHODS FOR THEIR PRODUCTION AND USE
ES2090331T3 (es) Ctaa 28a32, antigeno reconocido por mca 28a32.
ES2133395T3 (es) Anticuerpos monoclonales anti-idiotipicos contra el anticuerpo monoclonal especifico lewis y- br55-2, y sus usos.
ES2093135T3 (es) Anticuerpos monoclonales contra el complejo plasmina-antiplasmina, procedimiento para su preparacion asi como su utilizacion.
ATE97324T1 (de) Verwendung von amphipatischen molekuelen zur radiodarstellung und therapie mittels monoklonaler oder polyklonaler antikoerperkonjugate.
IT1254147B (it) Metodo di rivelazione di marcatori tumorali.
EP0089771A3 (en) Atcc hb8116 and its monoclonal anti-h-y antibody, hyclonalan

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 520499

Country of ref document: ES